Pharmacodynamic changes in tumor and immune cells drive iberdomide’s clinical mechanisms of activity in relapsed and refractory multiple myeloma-Reference-Cited by-同舟云学术

Pharmacodynamic changes in tumor and immune cells drive iberdomide’s clinical mechanisms of activity in relapsed and refractory multiple myeloma

Published:2024-06 Issue:6 Volume:5 Page:101571
ISSN:2666-3791
Container-title:Cell Reports Medicine
language:en
Short-container-title:Cell Reports Medicine

Author:

Amatangelo Michael,Flynt Erin^ORCID,Stong Nicholas,Ray Pradipta,Van Oekelen Oliver,Wang Maria,Ortiz Maria,Maciag Paulo,Peluso Teresa,Parekh Samir,van de Donk Niels W.C.J.,Lonial Sagar,Thakurta Anjan

Publisher

Elsevier BV

Reference53 articles.

1. Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial;Lonial;Lancet. Haematol.,2022

2. Molecular glue CELMoD compounds are regulators of cereblon conformation;Watson;Science,2022

3. Rate of CRL4CRBN substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4;Bjorklund;Blood Cancer J.,2015

4. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells;Kronke;Science,2014

5. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide;Lopez-Girona;Leukemia,2012

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Iberdomide increases innate and adaptive immune cell subsets in the bone marrow of patients with relapsed/refractory multiple myeloma;Cell Reports Medicine;2024-06